A Multicenter, Randomized, DoubleBlind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date22/11/2321/11/25

Keywords

  • Clinical trial
  • MK-4280A-010